切除可能境界域膵臓がん患者に対する術前化学療法の第I相試験。

基本情報

NCT ID

NCT02506803

ステータス

不明

試験のフェーズ

第1相

試験タイプ

介入

目標被験者数

10

治験依頼者名

Wakayama Medical University

概要

Gemcitabine plus nub-paclitaxel (GEMABR) regimen was recently presented at an international oncology meeting and represents a new standard regimen in the treatment of metastatic pancreatic cancer. Therefore, it was decided to consider the balance of safety and efficacy as a preoperative chemotherapy, the investigators use the NAC-GEMABR regimen includes only two cycles (three times weekly and one week rest) of GEMABR regimen.

対象疾患

介入

依頼者（Sponsor）

実施施設 (1)